RMD
ResMed Inc. · Healthcare · Medical - Instruments & Supplies
Momentum inputs (comparable managers):
holder breadth -6.2% ·
share flow +2.2% ·
net new positions -6.7%
· formula
Concentrated accumulation: rising shares among fewer holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q1 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 3 | 0 | 196.75K | $33.94M | n/a | −1 |
| Q2 2026 | 157 | +2 | 75.82M | $14.78B | +7 | −6 |
| Q1 2026 | 159 | +3 | 74.11M | $16.62B | +5 | −3 |
| Q4 2025 | 155 | -2 | 83.70M | $20.16B | +1 | −2 |
| Q3 2025 | 21 | 0 | 49.43M | $13.53B | n/a | −1 |
| Q2 2025 | 19 | +1 | 44.83M | $11.56B | +1 | n/a |
| Q1 2025 | 15 | -1 | 12.96M | $2.90B | n/a | −1 |
| Q4 2024 | 16 | -2 | 12.69M | $2.90B | n/a | −2 |
| Q3 2024 | 17 | +2 | 6.96M | $1.70B | +2 | n/a |
| Q2 2024 | 15 | n/a | 5.93M | $1.13B | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | State Street Global Advisors ✦ (passive) | 6.55M | +1.3% | $1.47B | 0.1% | ▲ Add | 2 | SEC ↗ |
| 2 | Geode Capital Management ✦ (passive) | 4.12M | +4.4% | $918.82M | 0.1% | ▲ Add | 4 | SEC ↗ ×2 |
| 3 | Norges Bank ✦ (passive) | 576.77K | +11.2% | $129.11M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 4 | Marshall Wace ✦ | 556.43K | +6987.4% | $124.56M | 0.2% | ▲ Add | 4 | SEC ↗ ×3 |
| 5 | AQR Capital Management ✦ | 402.42K | -35.6% | $88.19M | 0.1% | ▼ Trim | 4 | SEC ↗ ×6 |
| 6 | T. Rowe Price ✦ | 341.66K | +9.9% | $76.48M | 0.0% | ▲ Add | 4 | SEC ↗ ×2 |
| 7 | Bridgewater Associates ✦ | 119.33K | +36.7% | $26.71M | 0.1% | ▲ Add | 4 | SEC ↗ |
| 8 | Wellington Management ✦ | 58.20K | +549.7% | $13.03M | 0.0% | ▲ Add | 4 | SEC ↗ ×2 |
| 9 | Renaissance Technologies ✦ | 54.00K | -78.2% | $12.09M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 10 | Fisher Asset Management ✦ | 46.46K | +8.0% | $10.40M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 11 | Millennium Management ✦ | 38.54K | +55.2% | $8.63M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 12 | Citadel Advisors ✦ | 38.53K | -64.2% | $8.63M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 13 | Adage Capital Partners ✦ | 24.66K | -47.0% | $5.52M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 14 | Gotham Asset Management ✦ | 18.95K | -26.8% | $4.24M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 15 | D. E. Shaw & Co. ✦ | 17.64K | +169.3% | $3.95M | 0.0% | ▲ Add | 4 | SEC ↗ ×2 |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| No new tracked buyers this quarter. |
Exited
| Arrowstreet Capital | $49.43M | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 932 holders, 96.37M shares, $21.06B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer, Director · 4.99K sh · $1.13M
Officer, Director · 4.99K sh · $1.11M
Director · 970 sh · $227,688
Officer, Director · 4.99K sh · $1.03M
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology